Anti-PD-1 /PD-L1 antibody is effective in patients with high expression of PD-L1 and high TMB (TMB-H), especially in patients with non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, etc. [43, 44]. This evidence concerns the gene CD274 and melanoma.